Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ADTX

ADTX - Aditx Therapeutics Inc Stock Price, Fair Value and News

3.84USD-0.16 (-4.00%)Delayed as of 21 Feb 2024, 12:43 pm ET
Watchlist

Market Summary

USD3.84-0.16
Delayedas of 21 Feb 2024, 12:43 pm
-4.00%

ADTX Stock Price

View Fullscreen

ADTX RSI Chart

ADTX Valuation

Market Cap

1.8M

Price/Earnings (Trailing)

-0.06

Price/Sales (Trailing)

1.18

EV/EBITDA

0

Price/Free Cashflow

-0.11

ADTX Price/Sales (Trailing)

ADTX Profitability

EBT Margin

-1969.13%

Return on Equity

-26.28%

Return on Assets

-359.8%

Free Cashflow Yield

-901.55%

ADTX Fundamentals

ADTX Revenue

Revenue (TTM)

1.5M

Rev. Growth (Yr)

-86.33%

Rev. Growth (Qtr)

-80%

ADTX Earnings

Earnings (TTM)

-29.6M

Earnings Growth (Yr)

-28.96%

Earnings Growth (Qtr)

-71.52%

Breaking Down ADTX Revenue

52 Week Range

3.91
(Low)(High)

Last 7 days

5.2%

Last 30 days

-26.1%

Last 90 days

9.4%

Trailing 12 Months

-92.4%

How does ADTX drawdown profile look like?

ADTX Financial Health

Current Ratio

0.3

ADTX Investor Care

Shares Dilution (1Y)

324.74%

Diluted EPS (TTM)

-3.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20231.8M1.8M1.5M0
2022693.1K1.1M1.4M1.8M
2021000335.0K

Tracking the Latest Insider Buys and Sells of Aditx Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 07, 2023
bnp paribas securities corp
sold
-691,140
33.2279
-20,800
-
Jul 19, 2022
albanna amro a.
bought
20,000
20,000
1.00
chief executive officer
Jun 04, 2021
albanna amro a.
acquired
-
-
75,000
chief executive officer
Jun 04, 2021
albanna rowena
acquired
-
-
75,000
chief operating officer
Jun 04, 2021
pankovcin corinne
acquired
-
-
55,000
chief financial officer
Jun 01, 2021
albanna amro a.
bought
9,974
2.93353
3,400
chief executive officer
Jun 01, 2021
runge jeffrey w.
bought
29,343
2.93437
10,000
-
Jun 01, 2021
albanna rowena
bought
9,974
2.93353
3,400
chief operating officer
Jun 01, 2021
shabahang shahrokh
bought
1,435
2.93
490
chief innovation officer
May 27, 2021
shabahang shahrokh
bought
499
2.7
185
chief innovation officer

1–10 of 24

Which funds bought or sold ADTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
Schonfeld Strategic Advisors LLC
sold off
-100
-423,411
-
-%
Feb 13, 2024
MORGAN STANLEY
unchanged
-
-217
245
-%
Feb 13, 2024
Qube Research & Technologies Ltd
reduced
-41.67
-10,347
4,641
-%
Feb 13, 2024
ARMISTICE CAPITAL, LLC
sold off
-100
-349,720
-
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
reduced
-48.09
-17,028
6,478
-%
Feb 13, 2024
NATIXIS
unchanged
-
-1,708
1,575
-%
Feb 12, 2024
Glassman Wealth Services
new
-
3,315
3,315
-%
Feb 12, 2024
OSAIC HOLDINGS, INC.
unchanged
-
-64.00
72.00
-%
Feb 09, 2024
WELLS FARGO & COMPANY/MN
unchanged
-
-5.00
7.00
-%
Feb 09, 2024
UBS Group AG
added
138
2,699
12,803
-%

1–10 of 16

Are Funds Buying or Selling ADTX?

Are funds buying ADTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADTX
No. of Funds

Unveiling Aditx Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
cvi investments, inc.
0.5%
2,066
SC 13G/A
Feb 06, 2024
intracoastal capital, llc
1.5%
6,918
SC 13G/A
Jan 02, 2024
sabby management, llc
4.99%
22,048
SC 13G/A
Feb 14, 2023
cvi investments, inc.
9.9%
476,762
SC 13G/A
Feb 08, 2023
intracoastal capital, llc
5.8%
262,500
SC 13G/A
Jan 04, 2023
sabby management, llc
9.99%
415,697
SC 13G
Sep 27, 2022
cvi investments, inc.
9.9%
242,341
SC 13G
Sep 26, 2022
intracoastal capital, llc
9.99%
4
SC 13G
Jan 04, 2022
sabby management, llc
4.99%
2,170,897
SC 13G/A
Sep 03, 2021
sabby management, llc
9.99%
1,935,221
SC 13G

Recent SEC filings of Aditx Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 16, 2024
8-K
Current Report
Feb 15, 2024
8-K
Current Report
Feb 14, 2024
S-1/A
Initial Public Offering
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
8-K
Current Report
Feb 06, 2024
8-K
Current Report
Feb 06, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
425
Prospectus Filed
Feb 02, 2024
8-K
Current Report
Jan 30, 2024
8-K
Current Report

Peers (Alternatives to Aditx Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.2B
9.1B
-16.59% -47.80%
-9.57
3.64
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
18.9B
1.8B
-23.99% -31.71%
-42.82
10.31
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.61
7.23
15.05% 75.21%
13.2B
3.7B
-7.62% -26.87%
22.1
3.57
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.27
29.46
141.38% 4.43%
6.3B
107.9M
-3.85% 226.12%
-10.03
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-19.02
17.18
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.2
15.04
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.7
4.22
81.69% -7.29%
490.6M
1.0B
-9.17% -57.89%
-0.89
0.47
-43.15% 58.48%
185.9M
4.9M
-14.18% -58.18%
-1.13
38.02
-57.57% 50.48%
103.1M
881.7K
289.54% 381.25%
-2.17
112.79
-77.61% -13.74%
4.4M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aditx Therapeutics Inc News

Latest updates
Investing.com2 months ago

Aditx Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q4
Revenue-80.0%44,186220,978218,4151,019,407323,125214,715210,279-
Gross Profit-50.2%17,56435,24040,10615,43089,44139,85722,208-
Operating Expenses90.0%8,112,7734,269,6775,822,0018,215,4765,481,6055,810,8146,139,13924,020,799
  S&GA Expenses6202.7%7,169,863113,7594,368,8435,130,3293,919,618833,9424,624,15821,831,827
  R&D Expenses85.4%898,724484,8351,387,5413,081,2421,570,5401,187,9201,428,3821,702,370
EBITDA Margin-28.4%-18.88-14.70-14.86-14.97-30.58-43.10-65.84-137
Interest Expenses----12,737669,470---
Earnings Before Taxes-71.5%-9,745,902-5,682,018-5,984,706-8,183,166-7,557,563-5,850,006-6,059,141-24,052,532
EBT Margin-28.0%-19.69-15.38-15.53-15.64-30.88-43.49-66.44-138
Net Income-71.5%-9,745,902-5,682,018-5,984,706-8,183,166-7,557,563-5,850,006-6,059,141-24,052,532
Net Income Margin-28.0%-19.69-15.38-15.53-15.64-30.88-43.49-66.44-138
Free Cashflow-144.8%-8,033,931-3,281,828-3,951,791-6,719,974-7,818,429-2,654,299-5,199,304-8,691,275
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets12.8%8,2267,2947,63410,73519,18010,74011,79216,66419,58715,90518,01713,09715,368---
  Current Assets59.6%3,4282,1481,9434,74412,6253,6384,4419,41712,3869,92714,80911,03314,27875.00-4.00
    Cash Equivalents165035.4%1,6511.003032,7699,2458042,1157,8725,4698,61014,04510,50113,71650.0047.004.00
  Inventory-15.7%8581,018-950------------
  Net PPE-2,004--2,319------------
Liabilities11.5%12,44711,1637,5665,5296,4859,3797,0696,4836,6149,9416,6472,0851,6214,3303,6532,976
  Current Liabilities15.4%11,2439,7445,9103,6444,3737,0414,5153,6073,6015,2283,4051,2277564,330-2,976
Shareholder's Equity9.3%112,600103,03968.005,20612,6941,3614,72310,18112,9725,96411,37011,01113,7479,9399,5939,063
  Retained Earnings-9.3%-116,620-106,707-101,025-95,040-86,828-79,261-73,411-67,352-43,300-33,437-27,258-20,879-16,198-13,453--11,729
  Additional Paid-In Capital9.3%112,600103,033101,290100,44899,72080,76978,29277,73556,45039,58838,81632,07930,1359,939-9,063
Shares Outstanding-6.8%15816912146.0027.0023.0022.0010.009.007.007.006.003.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q2
Cashflow From Operations-144.8%-8,033-3,281-3,951-6,719-7,818-2,654-5,199-8,691-4,525-5,007-4,053-3,146-3,669-154-250---
  Share Based Compensation-5.7%1541633396146321,2846011,5048997721,4651,625874160529---
Cashflow From Investing-467700.0%-9.36-2*-5.0518087.00-135-373-8,482-7,041-294-486-------
Cashflow From Financing212.1%9,5993,0751,49164.0016,1721,479-18419,5768,427-1338,084-58.4817,495158293---

ADTX Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
REVENUE    
Sales$ 124,486$ 323,125$ 563,879$ 748,119
Cost of goods sold106,922233,684470,969596,613
Gross Profit17,56489,44192,910151,506
OPERATING EXPENSES    
General and administrative expenses $103,031, $461,492, $484,502, and $1,288,829 in stock-based compensation, respectively7,169,8633,919,61815,209,78912,332,728
Research and development, includes $49,209, $170,066, $165,382, and $473,593 in stock-based compensation, respectively898,7241,570,5402,771,1004,186,842
Sales and marketing $1,752, $0, $6,787, and $754,699 in stock-based compensation, respectively44,186(8,553)223,562911,988
Total operating expenses8,112,7735,481,60518,204,45117,431,558
NET LOSS FROM OPERATIONS(8,095,209)(5,392,164)(18,111,541)(17,280,052)
OTHER EXPENSE    
Interest expense(906,104)(645,381)(2,389,627)(742,701)
Interest income36710,0849,78430,131
Other income58,960
Amortization of debt discount(744,956)(1,530,102)(921,242)(1,533,048)
Total other expense(1,650,693)(2,165,399)(3,301,085)(2,186,658)
Net loss before income taxes(9,745,902)(7,557,563)(21,412,626)(19,466,710)
Income tax provision
NET LOSS(9,745,902)(7,557,563)(21,412,626)(19,466,710)
Implied Dividends(167,169)(167,169)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS$ (9,913,071)$ (7,557,563)$ (21,579,795)$ (19,466,710)
Net loss per share - basic (in Dollars per share)$ (48.77)$ (210.93)$ (136.94)$ (720.54)
Weighted average number of shares outstanding during the period - basic (in Shares)203,24735,829157,58427,017

ADTX Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash$ 1,651,354$ 2,768,640
Accounts receivable, net362,708527,961
Inventory858,106950,093
Prepaid expenses555,631496,869
TOTAL CURRENT ASSETS3,427,7994,743,563
Fixed assets, net2,003,8592,318,863
Intangible assets, net26,750107,000
Deposits312,265355,366
Right of use asset - long term2,454,8863,160,457
Deferred issuance costs50,000
TOTAL ASSETS8,225,55910,735,249
CURRENT LIABILITIES:  
Accounts payable and accrued expenses4,224,4251,958,502
Notes payable, net of discount4,020,055
Financing on fixed assets147,823409,983
Deferred rent169,633188,581
Lease liability - current1,081,3771,086,658
Settlement liability1,600,000 
TOTAL CURRENT LIABILITIES11,243,3133,643,724
Lease liability - long term1,203,8761,885,218
TOTAL LIABILITIES12,447,1895,528,942
STOCKHOLDERS’ EQUITY (DEFICIT)  
Preferred stock, value
Common stock, $0.001 par value, 100,000,000 shares authorized, 367,902 and 107,698 shares issued and 367,851 and 107,647 shares outstanding, respectively368108
Treasury stock, 51 and 51 shares, respectively(201,605)(201,605)
Additional paid-in capital112,599,764100,448,166
Accumulated deficit(116,620,157)(95,040,362)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)(4,221,630)5,206,307
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)8,225,55910,735,249
Series B Preferred stock  
STOCKHOLDERS’ EQUITY (DEFICIT)  
Preferred stock, value
Series C Preferred stock  
STOCKHOLDERS’ EQUITY (DEFICIT)  
Preferred stock, value
ADTX
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
 CEO
 WEBSITEwww.aditxt.com
 EMPLOYEES61

Aditx Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aditx Therapeutics Inc? What does ADTX stand for in stocks?

ADTX is the stock ticker symbol of Aditx Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aditx Therapeutics Inc (ADTX)?

As of Tue Feb 20 2024, market cap of Aditx Therapeutics Inc is 1.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADTX stock?

You can check ADTX's fair value in chart for subscribers.

What is the fair value of ADTX stock?

You can check ADTX's fair value in chart for subscribers. The fair value of Aditx Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aditx Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aditx Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ADTX is over valued or under valued. Whether Aditx Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aditx Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADTX.

What is Aditx Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, ADTX's PE ratio (Price to Earnings) is -0.06 and Price to Sales (PS) ratio is 1.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADTX PE ratio will change depending on the future growth rate expectations of investors.